| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Department of Pathology, Nagoya University School of Medicine, Showa-ku, Nagoya 466-8550 [K. K., T. I., H. M., K-i. I., A. N., M. T.]; Division of Experimental Animal Research, Life Science Tsukuba Research Center, The Institute of Physical and Chemical Research (RIKEN), Tsukuba, 305-0074 [N. H., A. Y., M. K.]; and Department of Pathology, Tosei General Hospital, Seto 489-8642 [K. O.], Japan
Germ line mutations of the RET proto-oncogene are
responsible for the development of multiple endocrine neoplasia type 2A
(MEN 2A), an inherited cancer syndrome characterized by medullary
thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia. To
study the mechanism of tissue-specific tumor development by
RET with a MEN2A (cysteine
634
arginine) mutation, we generated transgenic mice by introducing
the RET-MEN2A gene fused to Moloney murine leukemia
virus long terminal repeat. Expression of the transgene and its product
was detected at variable levels in a variety of tissues including
thyroid, heart, liver, colon, parotid gland, and brain. All of 29 mice
analyzed developed thyroid C-cell hyperplasia or medullary carcinoma,
accompanying high levels of serum calcitonin. In addition, development
of mammary or parotid gland adenocarcinoma was observed in one-half of
the transgenic mice. RET dimerization and its complex formation with
Shc and Grb2 adaptor proteins were detected in tumor tissues.
Unexpectedly, no tumor formation was found in other tissues despite
RET-MEN2A expression where RET dimerization was
undetectable. Because these tissues but not tumors expressed glial cell
line-derived neurotrophic factor family receptor
(GFR
) at high
levels, this suggested that GFR
expression may interfere in the
dimerization of the RET-MEN2A mutant proteins, leading to
tissue-specific tumor development in vivo.
This article has been cited by other articles:
![]() |
D. E. Costea, K. Kulasekara, E. Neppelberg, A. C. Johannessen, and O. K. Vintermyr Species-Specific Fibroblasts Required for Triggering Invasiveness of Partially Transformed Oral Keratinocytes Am. J. Pathol., June 1, 2006; 168(6): 1889 - 1897. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Strock, J.-I. Park, D. M. Rosen, B. Ruggeri, S. R. Denmeade, D. W. Ball, and B. D. Nelkin Activity of Irinotecan and the Tyrosine Kinase Inhibitor CEP-751 in Medullary Thyroid Cancer J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 79 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Read, P. J. Goodfellow, E. R. Mardis, N. Novak, J. R. Armstrong, and R. L. Cagan A Drosophila Model of Multiple Endocrine Neoplasia Type 2 Genetics, November 1, 2005; 171(3): 1057 - 1081. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Machens, P. Niccoli-Sire, J. Hoegel, K. Frank-Raue, T. J. van Vroonhoven, H.-D. Roeher, R. A. Wahl, P. Lamesch, F. Raue, B. Conte-Devolx, et al. Early Malignant Progression of Hereditary Medullary Thyroid Cancer N. Engl. J. Med., October 16, 2003; 349(16): 1517 - 1525. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Strock, J.-I. Park, M. Rosen, C. Dionne, B. Ruggeri, S. Jones-Bolin, S. R. Denmeade, D. W. Ball, and B. D. Nelkin CEP-701 and CEP-751 Inhibit Constitutively Activated RET Tyrosine Kinase Activity and Block Medullary Thyroid Carcinoma Cell Growth Cancer Res., September 1, 2003; 63(17): 5559 - 5563. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. G. Kroll Molecular Rearrangements and Morphology in Thyroid Cancer Am. J. Pathol., June 1, 2002; 160(6): 1941 - 1944. [Full Text] [PDF] |
||||
![]() |
M. Lindahl, D. Poteryaev, L. Yu, U. Arumae, T. Timmusk, I. Bongarzone, A. Aiello, M. A. Pierotti, M. S. Airaksinen, and M. Saarma Human Glial Cell Line-derived Neurotrophic Factor Receptor alpha 4 Is the Receptor for Persephin and Is Predominantly Expressed in Normal and Malignant Thyroid Medullary Cells J. Biol. Chem., March 16, 2001; 276(12): 9344 - 9351. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Qiao, T. Iwashita, T. Furukawa, M. Yamamoto, G. Sobue, and M. Takahashi Differential Effects of Leukocyte Common Antigen-related Protein on Biochemical and Biological Activities of RET-MEN2A and RET-MEN2B Mutant Proteins J. Biol. Chem., March 16, 2001; 276(12): 9460 - 9467. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |